Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial

This publication has 25 references indexed in Scilit:

• Trivalent MDCK cell culture-derived influenza vaccine Optaflu^®(Novartis Vaccines)
  Expert Review of Vaccines, 2009
• Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials
  Vaccine, 2009
• Current status and progress of prepandemic and pandemic influenza vaccine development
  Expert Review of Vaccines, 2009
• MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
  PLOS ONE, 2009
• An Adjuvanted, Low‐Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross‐Reactive Immune Responses in Healthy Adults
  The Journal of Infectious Diseases, 2008
• A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture
  New England Journal of Medicine, 2008
• A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine
  Vaccine, 2008
• MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
  Expert Review of Vaccines, 2007
• Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial
  The Lancet, 2007
• Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine
  New England Journal of Medicine, 2006